Tempest Therapeutics, Inc. — Director's Dealing 2017

Jun 24, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-06-21

Reporting Person: HOWE JOHN P MD (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-21	Stock Option (right to buy)	$1.46	A	12000	Acquired	2027-06-21	Common Stock (12000)	Direct

Footnotes

F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following June 21, 2017.